hepatitis B

Benzinga recently had the chance to chat with Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., who explained what RNA interference is and how it is used to treat genetic diseases. Beyond this theoretical explanation, the exec walked us through the company’s...

Benzinga recently had the chance to chat with Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., who explained what RNA interference (RNAI) is and how it is used to treat genetic diseases. Beyond this theoretical explanation, the exec elaborated on the company...

Ever heard of RNA Interference? In case you haven’t, Benzinga reached out to Dicerna Pharmaceuticals Inc (NASDAQ: DRNA)’s CEO Douglas M. Fambrough, Ph.D., and asked him to explain how it works. Silencing Genes “RNA Interference (RNAI) is a natural process. It is a biological...

Chardan has upgraded Arbutus Biopharma Corp (NASDAQ: ABUS) to Neutral following its underperformance versus Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and the S&P biotech index. Over the past month, Arbutus shares have dropped 26 percent, in contrast to both Arrowhead shares (+11 percent) and...

On Tuesday, Jefferies issued a company note on Gilead Sciences, Inc. (NASDAQ: GILD) after an "R&D Day" showed that potential drug candidates in the hepatitis B market may prove effective. Currently, analysts at Jefferies rate Gilead as a Hold with an $100 price target. Brian Abrahams and...